<?xml version="1.0" encoding="UTF-8"?>
<p>If the patientâ€™s travel or exposure history or symptoms suggest possible infection with a high-risk, novel agent, SARS-CoV, or MERS-CoV, then the initial handling of the specimen should be performed under biosafety level 3 (BSL-3) conditions until the specimen or an aliquot is rendered noninfectious by lysis or another method. Virus isolation should not be routinely performed in this situation (
 <ext-link ext-link-type="uri" xlink:href="https://www.asm.org/Articles/Policy/Laboratory-Response-Network-LRN-Sentinel-Level-C" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.asm.org/Articles/Policy/Laboratory-Response-Network-LRN-Sentinel-Level-C</ext-link>. Accessed 4 February 2020). The U.S. CDC biosafety guidelines state that routine diagnostic testing of specimens from suspected or confirmed SARS-CoV-2 patients, can be handled in a BSL-2 laboratory using standard precautions (
 <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html</ext-link>. Accessed 21 March 2020).
</p>
